Metformin attenuates hypoxia‑induced resistance to cisplatin in the HepG2 cell line

  • Authors:
    • Hiromasa Fujita
    • Katsumi Hirose
    • Mariko Sato
    • Ichitaro Fujioka
    • Tamaki Fujita
    • Masahiko Aoki
    • Yoshihiro Takai
  • View Affiliations

  • Published online on: December 24, 2018     https://doi.org/10.3892/ol.2018.9869
  • Pages: 2431-2440
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hepatoblastoma is the most commonly occurring liver tumor in children. Preoperative chemotherapy and surgery have improved treatment outcomes; however, further improvements are required in the treatment of advanced cases. Recently, the efficacy of transarterial chemoembolization (TACE) has garnered attention. TACE increases the local concentration of drugs by transcatheterically administering antitumor agents, and induces necrosis in the tumor by embolizing the feeding artery. However, studies have revealed that tumors exhibit resistance to anticancer drugs in hypoxic environments. Metformin is a drug used to treat type 2 diabetes; however, recent reports have indicated that it may also exhibit antitumor effects in various cancer cell lines. These effects are hypothesized to be mediated by the activation of adenosine monophosphate‑activated protein kinase and reduction of mammalian target of rapamycin signaling, but these effects occur at high concentrations that are not suitable for use in a clinical setting. The potential efficacy of metformin at increased physiological concentrations has not been evaluated. The present study investigated the therapeutic effect of low concentrations of metformin in combination with cisplatin on liver cancer HepG2 cells in hypoxic conditions. HepG2 cells were treated with cisplatin alone, metformin alone, or a combination of these two drugs and cultured in normoxia or hypoxia. Treatment with either 5 µM cisplatin or 1 mM metformin alone did not significantly affect cell proliferation or apoptosis in hypoxic conditions. However, when 5 µM cisplatin was combined with 1 mM metformin, a significant inhibition of cell proliferation and induction of apoptosis was observed in hypoxic HepG2 cells. In conclusion, a low concentration of metformin attenuates hypoxia‑induced resistance to cisplatin in HepG2 cells. Selective delivery of an effective dose of metformin to a hepatoblastoma tumor may be achievable and clinically useful with TACE.
View Figures
View References

Related Articles

Journal Cover

February-2019
Volume 17 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Fujita H, Hirose K, Sato M, Fujioka I, Fujita T, Aoki M and Takai Y: Metformin attenuates hypoxia‑induced resistance to cisplatin in the HepG2 cell line. Oncol Lett 17: 2431-2440, 2019
APA
Fujita, H., Hirose, K., Sato, M., Fujioka, I., Fujita, T., Aoki, M., & Takai, Y. (2019). Metformin attenuates hypoxia‑induced resistance to cisplatin in the HepG2 cell line. Oncology Letters, 17, 2431-2440. https://doi.org/10.3892/ol.2018.9869
MLA
Fujita, H., Hirose, K., Sato, M., Fujioka, I., Fujita, T., Aoki, M., Takai, Y."Metformin attenuates hypoxia‑induced resistance to cisplatin in the HepG2 cell line". Oncology Letters 17.2 (2019): 2431-2440.
Chicago
Fujita, H., Hirose, K., Sato, M., Fujioka, I., Fujita, T., Aoki, M., Takai, Y."Metformin attenuates hypoxia‑induced resistance to cisplatin in the HepG2 cell line". Oncology Letters 17, no. 2 (2019): 2431-2440. https://doi.org/10.3892/ol.2018.9869